 SERENITY I II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application NDA submission to U.S. Food and Drug Administration FDA planned for Q1 2021 Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patientsInitiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab KEYTRUDA to include patients with castrate-resistant prostate cancer CRPCStrengthened balance sheet through follow-on offering raising approximately 200 million in gross proceedsCompany to host conference call today at 8:30 a.m. ETNEW HAVEN, Conn., Aug. 14, 2020 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. BTI or Company Nasdaq: BTAI, a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced its quarterly results for the second quarter ended June 30, 2020 and provided an update on key strategic and operational initiatives.Since inception, this is one of the most exciting times in the Companys history, stated Vimal Mehta, Chief Executive Officer of BTI. First and foremost, we reported positive results from our two pivotal SERENITY trials last month that showed a robust treatment effect in reducing acute agitation in schizophrenia and bipolar disorder patients. We look forward to submitting an NDA for BXCL501 to the FDA in the first quarter of 2021 and, in preparation for a potential approval, we have made two key hires to lead commercialization and medical affairs. At the same time, we are advancing the TRANQUILITY and RELEASE trials in dementia and opioid withdrawal patients, respectively, and plan to initiate a trial in agitation associated with delirium patients this year, highlighting this candidates expected versatility across a wide range of diagnoses. We also continue to explore alternative indications associated with agitation, including alcohol withdrawal, post-traumatic stress disorder, traumatic brain injury and phobias. Finally, the successful completion of our recent follow-on equity offering puts us in a strong cash position to support BXCL501s commercial launch, if approved, and our aggressive indication expansion strategy.Dr. Mehta continued, In addition, our immuno-oncology program is advancing. The Phase 2 efficacy trial of BXCL701 and KEYTRUDA for treatment emergent Neuroendocrine Prostate Cancer continues to progress on track, and we have expanded this study to include a separate cohort of men with CRPC. Our MD Anderson-led Phase 2 basket trial in advanced solid tumors is also making great strides, now having met the efficacy bar in both arms necessary for the study to proceed to completion. We believe BXCL701 has the potential to bridge innate and adaptive immunity, as demonstrated by the increase in IL-18 from baseline, and we look forward to reporting initial efficacy data from both trials later this year.Second Quarter 2020 and Recent HighlightsBXCL501-Neuroscience ProgramBXCL501 is an investigational sublingual thin film of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, designed for the treatment of acute agitation. The Company believes BXCL501 may directly target a causal agitation mechanism. In July 2020, BTI reported that the pivotal Phase 3 SERENITY trials for the acute treatment of agitation in patients with schizophrenia and bipolar disorder met the primary, key secondary and exploratory endpoints. BXCL501 was well tolerated, with rapid and durable reductions in agitation. The Company has a pre-NDA meeting with the FDA this October and plans to submit an NDA for both indications in the first quarter of 2021. The Company is initiating a third dose cohort, 90 mcg, in the TRANQUILITY study, a Phase 1b2 trial of BXCL501 for the acute treatment of agitation associated with dementia. The adaptive trial is designed to identify the most effective and tolerable dose in this elderly patient population. BTI has successfully completed two lower-dose cohorts 30 mcg and 60 mcg in a total of 30 patients. Based on findings from the 90 mcg cohort, the Company expects to report topline results in the fourth quarter of 2020, or, if needed, proceed to an additional dose cohort. In June 2020, the first patient was enrolled in the RELEASE study, a Phase 1b2 trial of BXCL501 for the acute treatment of opioid withdrawal symptoms, with the third cohort currently enrolling 90 mcg twice a day, 12 hours apart. The Company expects to report topline results from the study in the first quarter of 2021. The Company expects to initiate a Phase 2 trial of BXCL501 in patients with agitation associated with delirium later this year. The planned study population will include ICU patients with or without COVID-19. This potential indication may offer synergy with the commercial infrastructure being developed to support our first NDA. The Company received a Notice of Allowance from the U.S. Patent and Trademark office for patient application No. 16453,679 related to BXCL501. The patent is expected to cover film formulations containing Dex and methods of treating agitation using such film formulations. The patent, which is anticipated to be issued in the third quarter of 2020, is expected to extend IP protection until 2039.BXCL701-Immuno-Oncology ProgramBXCL701 is an orally-delivered small molecule, innate immunity activator designed to inhibit dipeptidyl peptidase DPP 89 and block immune evasion by targeting Fibroblast Activation Protein FAP. It has shown single agent activity in melanoma and safety has been evaluated in more than 700 healthy subjects and cancer patients. The Phase 2 portion of the Phase 1b2 trial of BXCL701 in combination with pembrolizumab KEYTRUDA for treatment emergent Neuroendocrine Prostate Cancer tNEPC is advancing on track. Recently, BTI expanded the trial to include a separate cohort for CRPC adenocarcinoma patients who have failed taxane-based chemotherapy and up to two lines of second generation androgen pathway blockers, based on preliminary evidence of activity in this patient population in the safety cohort. The CRPC cohort is expected to run concurrently with the tNEPC cohort. Initial efficacy data from this trial are expected to be reported later this year. The open label Phase 2 basket trial evaluating the combination of BXCL701 and KEYTRUDA in patients with advanced solid cancers is proceeding, with early signs of clinical activity in several difficult-to-treat cancers. This study, which is being conducted at the MD Anderson Cancer Center, consists of two arms: checkpoint naïve patients and patients who are refractory to checkpoint therapy. In June, the safety portion of the trial was completed and in August, the efficacy bar was met for both arms of the trial, allowing the study to proceed to completion. Initial efficacy data are expected to be presented at a scientific conference later this year. The BXCL701 phase of the triple combination study of BXCL701, bempegaldesleukin NKTR-214, Nektar Therapeutics, Inc. and BAVENCIO avelumab, Merck KGaA, Darmstadt, Germany and Pfizer in second line pancreatic cancer is expected to begin following Nektar and Pfizers Phase 1b safety trial of a double combination of bempegaldesleukin and avelumab, pending the outcome of that trial. Corporate Highlights In July 2020, the Company raised gross proceeds of approximately 200 million in connection with its common stock offering. BTI believes that the proceeds from this offering, together with current reserves, provide cash runway well into 2022 to fund key clinical, regulatory, operational, and commercial activities. In June 2020, William Kane was appointed as Executive Vice President and Chief Commercial Officer of BTI. Mr. Kane brings over three decades of product commercialization experience in the pharmaceutical industry, with a proven track record in bringing neuropsychiatric drugs to market. In June 2020, Reina Benabou, M.D., Ph.D. was appointed as Senior Vice President and Chief Development Officer of BTI. Dr. Benabou has over 20 years of experience in directing drug development programs and implementing medical affairs strategies for product commercialization in neurology and psychiatry.COVID-19During the second quarter of 2020, the Company remained committed to ensuring the health and safety of its patients, investigators and employees. BTI continued to assess the impact of the COVID-19 pandemic to best mitigate risk, while continuing business operations. Beginning at the end of the second quarter, BTI began to slowly bring a limited number of staff back to the Companys office. This return to work is scheduled to be completed in September 2020. To date, the Companys business and operations has only been minimally impacted and have not experienced any significant delays to our ongoing or planned clinical trials, except for challenges in accessing elderly care facilities; however, this could rapidly change.Second Quarter 2020 Financial ResultsBTI reported a net loss of 21.4 million for the second quarter of 2020, compared to a net loss of 8.5 million for the same period in 2019. The second quarter 2020 results include approximately 2.0 million in non-cash stock-based compensation, compared to 1.0 million for the same period in 2019.Research and development expenses were 17.9 million for the second quarter of 2020, compared to 6.5 million for the same period in 2019. The increase was primarily due to increases in clinical trial activity.General and administrative expenses were 3.5 million for the second quarter of 2020, as compared to 2.1 million for the same period in 2019. The increase was primarily due to salaries, non-cash compensation costs and professional fees. 